We link multiple biomedical disciplines for research, training, and program development in the field of innate immunity.

IMPORTANT

SARS-CoV-2 and COVID-19

The CIIID is working with colleagues across the local, national, and global responses to SARS-CoV-2 infection and COVID-19 disease. Our member’s efforts include in-depth research and development activities to understand the virus-host interactions that regulate the innate and adaptive immune response to SARS-CoV-2 infection, to identify immune correlates of protection, build therapeutic antibodies, develop a novel vaccine against SARS-CoV-2, and identifying innate immune interventions to control COVID-19 disease.

For updates on local and global COVID-19 status, the following resources are available:

New paper from the Gale Lab describing a study led by Dr. Alison Kell shows that Hantavirus triggers innate immune actions in part through RLR signaling to differentially control virus in models of reservoir versus non-reservoir hosts.

This research has implications for disease following zoonotic virus transmission, and importantly points to additional, non-RLR innate immune programs impacting innate immunity against Hantaviruses across hosts.  Link to paper: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1008483

 

Dr. Katherine Wuertz completes her dissertation and returns to the US Army as Major

Data Stories | Understanding STING

See how researcher Kathryn McGuckin Wuertz is trying to understand the relationship between infectious diseases and neurological diseases

Gale laboratory and CIIID Director named among the Most Highly Cited Researchers of 2019

For the third year in a row the Gale lab and Dr. Michael Gale Jr. remain one of the most highly cited research groups in the world. Dr. Gale is the CIIID Director and is a Professor with the University of Washington Department of Immunology.

WOUND HEALING PROCESS COULD PROTECT AGAINST AIDS

Despite the development of effective therapeutics, HIV, the virus that causes AIDS, remains a major threat to humans worldwide. 37.9 million people are currently living with HIV, with 770,000 people dying of AIDS each year.  A cure for HIV is essential, but has not been made.  To better combat HIV, and to inform the development of new and better antiviral drugs to treat infection, an international group of scientists, led by Dr. Michael Gale, Jr., at the University of Washington, and Drs.